skip to Main Content
Newsfeed image, light gray text on dark gray background

Clinical Study Simplifies Precision Medicine for Pancreatic Cancer Patients

With more than 10 years of clinical and genomic data from the COMPASS trial, OICR-supported researchers have recently discovered a new, simplified way to match patients with the most appropriate treatment for their disease by measuring the expression of two genes, GATA6 and Keratin 5. Their discovery was recently published in Clinical Cancer Research. Read more…

Newsfeed image, light gray text on dark gray background

Screening for pancreatic cancer using artificial intelligence

Due to such a low incidence of this disease, screening the whole population is neither practical nor appropriate. Current diagnostic markers are very expensive per cancer and are challenged by cost and morbidity associated with invasive testing. Read more . . . 

Newsfeed image, light gray text on dark gray background

Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment

We show that KRAS mutation (KRAS*) drives cell-autonomous expression of type I cytokine receptor complexes (IL2rγ–IL4rα and IL2rγ–IL13rα1) in cancer cells that in turn are capable of receiving cytokine growth signals (IL4 or IL13) provided by invading Th2 cells in the microenvironment. Early neoplastic lesions show close proximity of cancer cells harboring KRAS* and Th2…

Newsfeed image, light gray text on dark gray background

Metastatic Pancreas Cancer; Salvage Therapy

Panelists: Edward Kim, MD, University of California Davis; John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center; Paul Oberstein, MD, NYU Langone Perlmutter Cancer Center; Allyson Ocean, MD, Weill Cornell Medical College; Shubham Pant, MD, The University of Texas MD Anderson Cancer Center. Watch here . . . 

Back To Top